Paysign at 17th Annual Midwest IDEAS Conference: growth broadens

Paysign (PAYS) highlighted a revenue inflection with first-half 2026 patient affordability revenue up 85%+ YoY and guided 2026 total revenue to $114M–$117M (from $82M in 2025). Margins and profitability look set to expand: gross margin is guided to 60%–62% and Adjusted EBITDA to $35M–$38M, with net income projected at $21.5M–$23M (diluted EPS $0.35–$0.37). Operationally, 50% of incremental Q2 revenue is said to convert to operating income, while the firm reports no bank debt and $30M+ unrestricted cash; the main risks flagged were plasma industry oversupply and insurer/PBM pushback in co-pays.

Analysis

The actionable read is not the headline growth rate, but the operating mix shift: PAYS is moving from a low-velocity payments utility to a higher-margin workflow layer embedded in pharma reimbursement. If that mix continues, the market may eventually stop valuing it like a niche processor and start treating it like a small software-enabled healthcare infrastructure name, which would justify multiple expansion more than the underlying top-line alone.

The second-order winners are large pharma names with heavy co-pay portfolios—ABBV, AZN, JNJ—because the economics of each program improve if leakage to maximizers is being intercepted more effectively. That said, this also invites more insurer/PBM scrutiny, so the benefit to pharma is partly offset by a longer-term risk that the policy debate shifts from "supporting adherence" to "subsidizing utilization," which could cap the runway in 6-18 months. On the loser side, the pressure is on incumbents with opaque pricing or broader hub models (IQV, MCK-linked support platforms) because PAYS is competing on transparency and speed rather than breadth.

The key near-term catalyst is not the investor presentation itself but whether the next 1-2 quarters confirm that incremental revenue still converts at unusually high rates. If patient-affordability program adds slow below management’s target, or average revenue per program stops rising, the margin story gets challenged fast. Longer-dated optionality sits in the plasma software stack: FDA timing on BEX is the real gating event, and until that clears, the software disruption thesis is more call option than base case.

Key Decisions for Investors

• Buy PAYS on post-event pullbacks, sized small due liquidity; use a 1-3 month horizon and keep the position only if patient-affordability revenue growth remains above ~50% y/y and 2026 program adds stay on track.
• Pair trade: long PAYS / short HAE for a 6-18 month relative-value expression on plasma software share gain; thesis fails if BEX FDA clearance slips materially or if Haemonetics response compresses pricing faster than expected.
• Add a modest long bias to ABBV and AZN as indirect beneficiaries of lower co-pay leakage; the trade works only if subsequent quarter disclosures show higher program utilization without a visible spike in regulatory pushback.
• Use IQV or MCK as a watchlist short, not a hard recommendation, pending evidence that PAYS is taking share in co-pay administration; confirm with program-win data rather than conference rhetoric.